Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data
Open Access
- 26 May 2004
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 47 (6), 969-975
- https://doi.org/10.1007/s00125-004-1409-4
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose ToleranceStroke, 2004
- Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic WomenDiabetes, 2002
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidenceDiabetologia, 2001
- The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening dataDiabetes Care, 1998
- The Effect of Acarbose on Insulin Sensitivity in Subjects With Impaired Glucose ToleranceDiabetes Care, 1996
- The Efficacy of Acarbose in the Treatment of Patients with Non–Insulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical TrialAnnals of Internal Medicine, 1994
- Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complicationsJournal Of Hypertension, 1993
- Scope and Specificity of Acarbose in Slowing Carbohydrate Absorption in ManDiabetes, 1981
- Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose IntoleranceDiabetes, 1979